Mazor Robotics Ltd. (NASDAQ:MZOR) had its price objective upped by Barclays PLC from $24.00 to $28.00 in a research note published on Tuesday. They currently have an overweight rating on the stock.

Several other brokerages have also recently weighed in on MZOR. Zacks Investment Research raised shares of Mazor Robotics from a sell rating to a hold rating and set a $22.00 price target on the stock in a research report on Tuesday, July 19th. B. Riley started coverage on shares of Mazor Robotics in a research report on Thursday, October 6th. They set a neutral rating and a $25.00 price target on the stock. Needham & Company LLC reissued a hold rating on shares of Mazor Robotics in a research report on Tuesday, August 2nd. Finally, Standpoint Research started coverage on shares of Mazor Robotics in a research report on Friday, July 8th. They set a buy rating and a $30.00 price target on the stock. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Mazor Robotics has a consensus rating of Hold and a consensus target price of $26.25.

Mazor Robotics (NASDAQ:MZOR) traded up 0.6355% during midday trading on Tuesday, reaching $25.3199. 42,314 shares of the company traded hands. The stock’s market capitalization is $548.76 million. Mazor Robotics has a one year low of $8.31 and a one year high of $26.55. The company has a 50 day moving average price of $23.33 and a 200-day moving average price of $18.19.

Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $8.51 million. Mazor Robotics had a negative net margin of 60.75% and a negative return on equity of 42.30%. The company’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.05) EPS. Analysts forecast that Mazor Robotics will post ($0.71) EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in MZOR. Iguana Healthcare Management LLC raised its stake in Mazor Robotics by 60.0% in the second quarter. Iguana Healthcare Management LLC now owns 200,000 shares of the company’s stock worth $3,596,000 after buying an additional 75,000 shares during the last quarter. Menta Capital LLC raised its stake in Mazor Robotics by 25.0% in the second quarter. Menta Capital LLC now owns 46,848 shares of the company’s stock worth $842,000 after buying an additional 9,366 shares during the last quarter. EAM Investors LLC purchased a new stake in Mazor Robotics during the second quarter worth $2,348,000. Cookson Peirce & Co. Inc. purchased a new stake in Mazor Robotics during the second quarter worth $192,000. Finally, Candriam Luxembourg S.C.A. purchased a new stake in Mazor Robotics during the second quarter worth $1,079,000. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

5 Day Chart for NASDAQ:MZOR

Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.